<DOC>
	<DOCNO>NCT01534494</DOCNO>
	<brief_summary>This trial open-label pilot study ( N = 10 ) design assess effect psilocybin alcohol dependent participant , demonstrate feasibility integrate behavioral/pharmacologic intervention , provide preliminary outcome safety data . Participants receive psilocybin orally two all-day administration session , conduct secure outpatient psychiatric setting , dose range well-tolerated recent study . Psilocybin administration occur context behavioral intervention include total 12 session 12 week , incorporate Motivational Enhancement Therapy ( MET ( Miller , Zweben et al . 1992 ; Miller 1995 ) , base Motivational Interviewing ( Miller Rollnick 2002 ) ) booster session , well preparation debrief psilocybin administration session . The MET incorporate attention spirituality well drink behavior primary subject change . Drinking outcome change several potential mediator treatment effect , include motivation , self-efficacy , craving , depression , anxiety , spiritual dimension experience , measure treatment 24 week end treatment . The investigator hypothesize drink decrease follow psilocybin session , increase motivation , self-efficacy , spirituality ( primary contrast 12 week vs. baseline ) observe among study participant .</brief_summary>
	<brief_title>Effects Therapeutic Potential Psilocybin Alcohol Dependence</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Psilocybine</mesh_term>
	<criteria>1 . Males females age 2565 SCID diagnosis alcohol dependence ; 2 . Concerned drinking , plan pursue form treatment present ( 12step meeting consider treatment ) ; 3 . Able provide voluntary inform consent ; 4 . Having least 2 heavy drinking day past 30 day ; 5 . Willing commit goal abstinence least time first psilocybin administration session end treatment . 6 . At least 24 hour abstinence alcohol time psilocybin administration session ; 7 . If female childbearing potential , willing use approve form contraception screen psilocybin administration session ; 8 . Having family member friend pick stay overnight psilocybin administration session ; 9 . Able provide adequate locator information . 1 . Exclusionary medical condition ( e.g. , seizure disorder , significantly impair liver function , coronary artery disease , uncontrolled hypertension , history cerebrovascular accident , severe obesity ( BMI great equal 35 ) ; 2 . Exclusionary psychiatric condition ( schizophrenia , schizoaffective disorder , bipolar disorder , current major depression , current posttraumatic stress disorder , current suicidality ) ; 3 . A family history schizophrenia , schizoaffective disorder , bipolar disorder , suicide ( first second degree relative ) ; 4 . Lifetime history hallucinogen use 10 occasion , use past 30 day ; 5 . Cocaine , psychostimulant , opioid dependence ( past 12 month ) current ( past 30 day ) use ; 6 . A history medically significant suicide attempt violent crime ; 7 . Significant alcohol withdrawal ( CIWAAr score great 7 ) ; 8 . Exclusionary laboratory abnormality ( liver function test ( LFT ) great 5 time normal , ECG evidence ischemia , serious abnormality complete blood count chemistry ) ; 9 . Active legal problem potential result incarceration ; 10 . Pregnancy lactation ; 11 . The need take exclude medication ( e.g. , antidepressant , antipsychotic , psychostimulants , pharmacologic treatment addiction ) . 12 . High risk adverse emotional reaction base investigator 's clinical evaluation ( e.g. , evidence serious personality disorder , serious current stressor , lack meaningful social support ) .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>alcohol dependence</keyword>
	<keyword>psilocybin</keyword>
	<keyword>clinical trial</keyword>
	<keyword>motivational enhancement therapy</keyword>
</DOC>